Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 5, 2013
Grant Date -
Nov 10, 2011
app pub date -
May 9, 2011
filing date -
Aug 4, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully